NCT00363077View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 2, 2006

Primary Completion Date

November 1, 2006

Study Completion Date

November 17, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

GSK1247446A Group

Low dose influenza vaccine adjuvanted with AS03 compared

BIOLOGICAL

Fluarix™

GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY